A4L Appoints William E. Sanders, Jr. MD MBA Chief Medical Officer And Nick Leb Chief Financial Officer

TORONTO, Jan. 12, 2016 /PRNewswire/ -- A4L (Analytics for Life Inc.), a medical information technology company that uses advanced signal processing techniques for the purposes of detecting and assessing disease, today announced the appointment of William E. (Gene) Sanders, Jr. MD MBA as Chief Medical Officer and Nick Leb as Chief Financial Officer.

"Gene and Nick are seasoned executives with substantial healthcare experience who will provide sound clinical, financial and strategic leadership as we continue to grow and build our management team," commented Don Crawford, President and CEO. "Gene will play an immediate key role in clinical site selection and investigator relations as we continue to prepare for our clinical trials in the coming months. Nick will establish the infrastructure and corporate governance required to sustain and expand our organization.  I am excited to welcome both to the A4L team."

Dr. Sanders is a cardiologist with 30 years of medical experience specializing in Clinical Cardiac Electrophysiology. Most recently Dr. Sanders served as FDA Medical Officer of the Cardiac Electrophysiology Device Branch within the Cardiovascular Devices Division. Previously, Dr. Sanders was an Associate Professor of Medicine and Pathology at University of North Carolina at Chapel Hill, where he spent 15 years as the Director of Clinical Cardiac Electrophysiology and Pacing and Associate Director of Cardiovascular Diagnostic and Interventional Laboratories. He has been directly involved in the success of multiple start-up medical device companies, acting as a consultant and board member.

Nick Leb is a proven financial executive with over 25 years of experience in public accounting, finance, treasury and investor relations in both publicly traded and privately held corporations. Nick joins A4L after serving as CFO for Sapheon Inc., which was recently acquired by Medtronic, where he was responsible for all accounting, finance and treasury functions for both the US parent corporation and the Dutch subsidiary. Previously, he served as CFO for KBI Biopharmaceuticals and Vice President of Finance for Accentia BioPharmaceuticals, TEAMM Pharmaceuticals, Brightstone Pharma and Global Surgical Corporation. He previously served as Corporate Controller for KV Pharmaceuticals and as a Director for Vyrix Pharmaceuticals, Inc. and BioVest International, Inc.

About A4L: A4L is a medical information technology company that is developing disruptive solutions for assessing and diagnosing disease, using proprietary variable extraction and machine learned algorithms. These non-invasive and cost-effective solutions reveal and analyze previously hidden information of the patient's health status from within their physiologic signals. A4L's focus is on developing a platform technology that has the potential to address various disease states.

MEDIA CONTACT:
Rebecca Raabe
SPRIG Consulting, LLC
(480) 440-5046
[email protected]

SOURCE A4L

Related Links

http://www.analytics4life.com